Taysha Gene Therapies shares are trading lower after the company announced longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial of TSHA-102 in Rett syndrome.
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies shares are trading lower following the announcement of longer-term clinical data from the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome.
June 18, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Taysha Gene Therapies shares are trading lower after the company announced longer-term clinical data from the ongoing REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome.
The release of longer-term clinical data from the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome has led to a decline in Taysha Gene Therapies' share price. This suggests that the market may have reacted negatively to the data, possibly due to concerns about the efficacy or safety of the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100